MedtechLedger currently links 6 FDA records to the applicant name Balt USA, LLC. The collection includes 3 510(k) clearances. It includes 1 original PMA approval. 2 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jan 27, 2026 to Oct 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Changes described in PMA records
The FDA record for P250009/S001, dated 2026-10-16, shows approval of the protocol for the COSMIC post-approval study, submitted under the normal 180-day track with no user fee. The supplement reason is listed as Postapproval Study Protocol, tied to the SQUID Liquid Embolic Agent (LEA), product code SGU, in neurology, submitted by Balt USA, LLC. The record does not describe the protocol's design, endpoints, sample size, or the conditions it addresses.
The source statement indicates the protocol was submitted to comply with conditions of approval in the original P250009 order. That wording is the agency's reported purpose, not independent evidence of safety or clinical effectiveness. The record does not show a change to the device's indications or labeling, and the six-character identifier alone does not confirm the original approval date or the full scope of the parent PMA. The decision applies to the PAS protocol, not a new approval of the whole system.
FDA approval-order wording
Approval of the protocol for the COSMIC post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250009.
Oct 16, 2026 · Normal 180 Day Track No User FeeThe FDA record for P250009/S002, dated 2026-09-09, shows an approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA). It is classified as a real-time process supplement under the labeling-change reason covering indications, instructions, shelf life, or tradename. The record lists the device category as a neurovascular liquid embolic agent and the specialty as neurology, with Balt USA, LLC as applicant. The specific before-and-after mixing times are not given in the supplied fields.
The S002 identifier links the action to the preceding PMA P250009 as a supplement, not a new approval of the whole system. The record's reported purpose describes a process change to mixing time; it does not establish safety or clinical effectiveness independently. The supplied fields also omit whether the change is accompanied by revised labeling text, what prompted the change, and which shelf-life or instruction sections were affected.
The supplement type is listed as "Real-Time Process," and the stated purpose is confined to the mixing time, so no broader technical detail, trial result, or new indication should be inferred from this entry.
FDA approval-order wording
Approval for changes to the mixing time for the SQUID Liquid Embolic Agent (LEA).
Sep 9, 2026 · Real-Time ProcessFDA approved the SQUID Liquid Embolic Agent from Balt USA, LLC on January 30, 2026. The approval covers embolization of the middle meningeal artery as an adjunct to usual care in patients with symptomatic chronic subdural hematoma measuring 10 mm or greater in thickness, when a neurosurgeon determines an intervention is necessary.
The database record lists the device category as neurovascular liquid embolic agent, the specialty as neurology, and the product code as SGU. The record does not include a supplement type or supplement reason, so no additional change to a prior approval is described. The statement reports an intended use; it does not independently establish safety or clinical effectiveness.
FDA approval-order wording
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness in whom an intervention is deemed necessary as determined by a neurosurgeon.
Jan 30, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.